Welcome to our dedicated page for Palisade Bio news (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.
Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company whose news flow centers on the development of its lead oral PDE4 inhibitor prodrug, PALI-2108, and related corporate and regulatory milestones. The company focuses on autoimmune, inflammatory, and fibrotic diseases, with particular emphasis on ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD).
News about Palisade Bio frequently highlights progress in its clinical programs. Recent announcements describe completion of Phase 1a and Phase 1b studies in UC, initiation and patient dosing in a Phase 1b study in FSCD, and plans to use these data to support Phase 2 IND submissions to the U.S. Food and Drug Administration. Company updates also discuss trial design elements such as safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory tissue-level and molecular analyses in intestinal biopsies and blood samples.
Investors and observers can also expect coverage of intellectual property developments, including composition-of-matter patents granted in Canada and Japan for PALI-2108 and related gut microbiota–activated PDE4 inhibitor prodrugs. Financing and capital markets activity is another recurring theme, with press releases detailing underwritten public offerings of common stock and common stock equivalents, as well as the intended use of proceeds to fund Phase 2 development in ulcerative colitis.
Additional Palisade Bio news items include participation in healthcare investor conferences, appointments of clinical and operational leaders with experience in gastroenterology and immunology, and governance matters such as stockholder meetings and special meeting outcomes. For readers following PALI, this news stream provides insight into the company’s clinical timelines, regulatory plans, patent estate, leadership, and financing decisions related to its gut-targeted PDE4 inhibitor prodrug platform.
Palisade Bio (Nasdaq: PALI) reported positive topline Phase 1b data for PALI-2108 in fibrostenotic Crohn’s disease on March 30, 2026. The 14-day study (n=5) showed favorable safety, a mean 47.5% reduction in SES-CD, 40% endoscopic response and remission rates, and pharmacokinetics supporting once-daily dosing with tissue levels above IC90.
Mean fecal calprotectin fell ~59%, ileal cAMP rose 41%, and ileal tissue exposure exceeded plasma (~3x ileum, ~5x colon). Company plans a Phase 2 in moderate-to-severe Crohn’s disease and will present data at upcoming conferences.
Palisade Bio (Nasdaq: PALI) announced management participation in two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 3:10 PM EST in Boston (in-person presentation and meetings) and the Leerink Partners 2026 Global Healthcare Conference on March 8-11, 2026 in Miami (one-on-one meetings).
Investors registered for each event who wish to meet with management should contact the respective conference one-on-one desk to request a meeting. A webcast registration link is available for the TD Cowen presentation.
Palisade Bio (Nasdaq: PALI) presented Phase 1b translational data for PALI-2108 at ECCO 2026 showing rapid, colon‑targeted activity. Key findings included measurable clinical response within seven days, localized suppression of inflammatory and fibrotic gene programs in colon tissue, reduced PDE4B expression with increased tissue cAMP, and an encouraging safety profile across 89 subjects. Analyses showed downregulation of TNF-α, JAK–STAT, NF-κB, MAPK and TGF-β signaling and reduced inflammatory cell signatures, while peripheral immune profiles remained largely unchanged, supporting a colon‑focused pharmacologic effect.
Palisade Bio (Nasdaq: PALI) appointed Bram Verstockt, MD, PhD, to its Clinical Advisory Board to strengthen clinical and translational expertise for PALI-2108.
The company plans a Phase 2 ulcerative colitis IND submission in the first half of 2026 and aims to advance PALI-2108 in UC and fibrostenotic Crohn’s disease.
Palisade Bio (Nasdaq: PALI) announced a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on Thursday, February 12, 2026, from 1:30 PM–1:55 PM ET. CEO JD Finley and President/CMO Dr. Mitchell Jones will present.
The event includes analyst-led discussions, one-on-one investor meetings for registered attendees, a live webcast on the company Events page at palisadebio.com, and a replay archived for a limited time.
Palisade Bio (Nasdaq: PALI) will present virtually at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The presentation runs 12:40 PM–1:10 PM ET in Track 3 and will be webcast live. Management will also hold one-on-one in-person meetings with qualified investors. A replay will be archived for a limited time on the company’s Investors Events page at palisadebio.com.
Palisade Bio (Nasdaq: PALI) appointed Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD to its Clinical Advisory Board to strengthen clinical strategy as PALI-2108 advances toward Phase 2 development. The company plans a Phase 2 UC IND submission in H1 2026 and focuses on targeted, once-daily oral PDE4 prodrugs for terminal ileum and colon delivery.
The advisors bring expertise in ulcerative colitis, Crohn’s disease, intestinal fibrosis, treat-to-target strategies, and late-stage trial design; Peyrin-Biroulet has authored >1200 peer-reviewed publications.
Palisade Bio (Nasdaq: PALI) announced two abstracts for its lead program PALI-2108 have been selected for poster presentations at major IBD meetings in early 2026. Presentations detail gut-targeted PDE4B inhibition and translational Phase 1a findings in ulcerative colitis.
Events and details: Crohn’s & Colitis Congress (Las Vegas) on Jan 23, 2026 — poster by James Izanec, MD; ECCO 2026 (Stockholm) on Feb 20, 2026 — poster P0989 by James Izanec, MD.
Palisade Bio (Nasdaq: PALI) announced a strategic equity investment of up to $500,000 from the Crohn’s & Colitis Foundation through its IBD Ventures program to support development of PALI-2108, a gut-microbiota-activated PDE4 inhibitor designed for targeted delivery to the terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and moderate to severe ulcerative colitis (UC).
Palisade has completed Phase 1a single- and multiple-ascending dose and food-effect studies, plus a Phase 1b cohort in UC, and is conducting a Phase 1b cohort in FSCD. Data from these studies are expected to support Phase 2 IND submissions to the FDA in 2026.
Palisade Bio (NASDAQ: PALI) announced the Japan Patent Office granted a composition-of-matter patent for PALI-2108, a gut-microbiota-activated PDE4 B/D inhibitor targeting fibrostenotic Crohn’s disease (FSCD) and moderate-to-severe ulcerative colitis (UC).
The base patent term extends into 2041 and is eligible for patent term extension based on regulatory review timelines. PALI-2108 has completed Phase 1a SAD/MAD and FE studies, a Phase 1b cohort in UC, and is in an ongoing Phase 1b cohort in FSCD. Data are expected to support a Phase 2 IND submission in H1 2026. The patent expands the company’s global IP estate for its locally-acting PDE4 prodrug platform.